GlassScriptPhysician profile
Nirav Gandhi
NPI 1649263252
$2,711.85
in general payments reported to CMS, 2019-2025
23 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2022: $153 · 2023: $564 · 2024: $588 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $736.38 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $627.44 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $346.53 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $144.84 | 2023-2025 | Ibsrela |
| Amgen INC. | $116.13 | 2024-2025 | Krystexxa, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $103.56 | 2023-2024 | |
| Travere Therapeutics, INC. | $94.59 | 2024 | |
| Vifor Pharma, INC. | $89.98 | 2024-2025 | Veltassa |
| Baxter Healthcare | $72.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.37 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $55.80 | 2019 | |
| Aurinia Pharma U.S., INC. | $55.09 | 2024 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $49.46 | 2025 | Empaveli |
| Novo Nordisk INC | $37.26 | 2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $33.03 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $25.11 | 2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $24.23 | 2025 | Tarpeyo |
| Nxstage Medical, INC. | $22.04 | 2025 | Nxstage System One |
| Scpharmaceuticals INC. | $21.86 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.